# Effectiveness and Safety of Palbociclib: Brand vs. Generic in Iraqi Stage IV Breast Cancer Patients

> **NCT07493291** · — · ACTIVE_NOT_RECRUITING · sponsor: **Al-Mustansiriyah University** · enrollment: 100 (estimated)

## Conditions studied

- Brest Cancer
- CDK4/6 Inhibitor

## Interventions

- **DRUG:** Palbociclib (Brand vs Generic) compartive

## Key facts

- **NCT ID:** NCT07493291
- **Lead sponsor:** Al-Mustansiriyah University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-09-07
- **Primary completion:** 2026-03-01
- **Final completion:** 2026-04-20
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07493291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07493291, "Effectiveness and Safety of Palbociclib: Brand vs. Generic in Iraqi Stage IV Breast Cancer Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07493291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*